Veterinary Resources


Check Out the Latest Webinars from ELIAS Animal Health

Treating Canine
Cancer with Killer T Cells

Recent advances in the fourth pillar of cancer treatment—immunotherapy—suggest that the immune system may be our best tool to cure more cancers. Watch this webinar to learn how the move to an immunotherapeutic approach to treat canine cancer can make a difference for your patients and their families.

Changing the Way Veterinarians Treat Canine Cancer

Pet owners and their families are urgently looking for new and better options to prolong their
companion’s life and improve the quality of life. How can you help these dogs and these families address this reality? Watch this webinar to learn more about the limitations of traditional treatments for canine osteosarcoma (amputation and chemotherapy) and how cutting edge cancer immunotherapies are opening new frontiers in veterinary medicine.

Can We Treat Canine Osteosarcoma Without Chemotherapy?

Jeffrey Bryan, DVM, DACVIM (O) and Brian Flesner, DVM, DACVIM (O) discuss immunotherapy, including adoptive T cell therapies for dogs. The hosts also review their recently
published results of an innovative treatment for osteosarcoma that included no radiation or


Trial Data Revealed

Autologous cancer cell vaccination, adoptive T‐cell transfer, and interleukin‐2 administration results in long‐term survival for companion dogs with osteosarcoma

Results of the ECI® osteosarcoma treatment were published in the Journal of Veterinary Internal Medicine (July 2020) with the researchers determining it to be safe and tolerable in the study. Median Survival Time for dogs completing the osteosarcoma protocol was 415 days. It was further noted that this median survival time exceeded those typically reported for those patients receiving amputation plus chemotherapy. The promise of improved survival rates and prolonged life for cancer patients is being revealed in the data.

First published 10 July 2020

C.A.S.E ..S.T.U.D.I.E.S

Real Families. Real Cases. Real Results.


“I really think that there is strong evidence that the ELIAS procedure benefited these dogs, substantially
and on average, based on that median survival. I will also point out that every single piece of the ELIAS
immunotherapy process is extremely well supported in the scientific literature across multiple species.”

Jeffrey Bryan, DVM, DACVIM (Oncology), University of Missouri

“There’s going to be a never-ending irreversible limitation of what autologous vaccine alone can do, which is why I’m attracted to the ECI product because of the activated T cell component. I don’t think that any of
these products or autologous vaccines that are out there today are that much different or are going to offer that much significant difference. Whereas I think ECI has some clear improvements and should
result in better results and better outcomes.”

K. Ann Jeglum, VMD, DACVIM (Oncology), Veterinary Oncology Services and Research Center

Make a Difference For Your Patients